Juno Therapeutics, Inc.
Juno Therapeutics, Inc. (JUNO): 17 pipeline candidates · 2 clinical trials. Updated within the last hour.
BioSniper Score
3-factor signal · derived from public data
N/A
0% dilution
Lead: Phase 3
17 candidates
N/A
N/A
A transparent, data-derived signal for Juno Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$232.8M
Quarterly Burn
—
Runway
—
Revenue
$26.5M
Pipeline (17 candidates)
| Drug | Phase |
|---|---|
| arlocabtagene autoleucel | Phase 3 |
| bms-986353 | Phase 2 |
| bms-986393 | Phase 3 |
| bms-986515 | Phase 1 |
| calcium folinate | Phase 2 |
| cc-97540 | Phase 2 |
| daratumumab | Phase 3 |
| fcarh143 | Phase 1 |
| fludarabine | Phase 1 |
| jcar014 | Phase 1 |
Showing 10 of 17 candidates. Sign up for full pipeline.
Frequently asked questions
How many drug candidates are in Juno Therapeutics, Inc.'s pipeline?
Juno Therapeutics, Inc. (JUNO) has 17 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Juno Therapeutics, Inc.'s lead drug candidate?
Juno Therapeutics, Inc.'s most advanced tracked candidate is arlocabtagene autoleucel (Phase 3) for Multiple Myeloma.
Who is the CEO of Juno Therapeutics, Inc.?
Hans E. Bishop is the chief executive officer of Juno Therapeutics, Inc. (JUNO).
Get the full picture on Juno Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.